We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Align Unveils Vivera Retainers for Deep Bite Correction
Read MoreHide Full Article
Align Technology, Inc. (ALGN - Free Report) has made an extension to its Invisalign clear aligner range with the latest launch of Vivera Retainers with Precision Bite Ramps. This is claimed to be the first-of-its retainers in the market, which can be customized to provide additional support after a deep bite correction.
Notably, Vivera retainer is made with the same state-of-the-art technology as Invisalign aligners. It employs 3-D digital imaging, proprietary clear thermoplastic material and advanced fabrication technology for a stronger retention with a precise, comfortable fit.
Per Align, Precision Bite Ramps were first introduced in 2014 and are designed to disocclude the posterior teeth or “open the bite”. This improves efficiency in deep bite Invisalign treatments. Since Precision Bite Ramps are part of Invisalign G5, its integration with Vivera Retainers is expected to bring greater clinical success for Align in the orthodontic space.
With deep bite malocclusion gradually becoming a very common orthodontic occurrence worldwide, we consider this development a major breakthrough for Align with respect to customer adoption. The rate of deep bite malocclusion cases is mostly high in North America and EMEA, registering 45% of patients from those regions.
According to statistics provided by Align, till date, more than 688,000 moderate or severe deep bite patients (including over 185,000 teenagers) have been treated with Invisalign clear aligners. Patient data also showed that doctors are increasingly fixing severe deep bites with Invisalign G5 Precision Bite Ramps.
It is important to note that Align has recently undertaken several strategies to improve adoption of Invisalign Technology globally including product/technology development, extending clinical effectiveness, expansion of the Invisalign Technology brand and driving international growth. In a parallel press release today, the company has introduced an expanded Invisalign product portfolio offering new options and greater flexibility to a wider range of patients.
Earlier, the company had introduced a clear Aligner solution for teen Class II correction — the Invisalign Technology Teen with mandibular advancement — in certain markets of Canada, EMEA and APAC. These are indicative of the growing popularity of Align’s dental products in the international market. Over the long term, we expect G6, G7 and similar innovations to act as major catalysts for Align in the new as well as the existing markets.
Over the past six months, shares of Align have outperformed its industry. The stock has surged 33.1% compared with the 2.1% increase of the industry.
Zacks Rank & Key Picks
Align carries a Zacks Rank #2 (Buy). A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Edwards Lifesciences Corporation (EW - Free Report) .
athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Align Unveils Vivera Retainers for Deep Bite Correction
Align Technology, Inc. (ALGN - Free Report) has made an extension to its Invisalign clear aligner range with the latest launch of Vivera Retainers with Precision Bite Ramps. This is claimed to be the first-of-its retainers in the market, which can be customized to provide additional support after a deep bite correction.
Notably, Vivera retainer is made with the same state-of-the-art technology as Invisalign aligners. It employs 3-D digital imaging, proprietary clear thermoplastic material and advanced fabrication technology for a stronger retention with a precise, comfortable fit.
Per Align, Precision Bite Ramps were first introduced in 2014 and are designed to disocclude the posterior teeth or “open the bite”. This improves efficiency in deep bite Invisalign treatments. Since Precision Bite Ramps are part of Invisalign G5, its integration with Vivera Retainers is expected to bring greater clinical success for Align in the orthodontic space.
With deep bite malocclusion gradually becoming a very common orthodontic occurrence worldwide, we consider this development a major breakthrough for Align with respect to customer adoption. The rate of deep bite malocclusion cases is mostly high in North America and EMEA, registering 45% of patients from those regions.
According to statistics provided by Align, till date, more than 688,000 moderate or severe deep bite patients (including over 185,000 teenagers) have been treated with Invisalign clear aligners. Patient data also showed that doctors are increasingly fixing severe deep bites with Invisalign G5 Precision Bite Ramps.
It is important to note that Align has recently undertaken several strategies to improve adoption of Invisalign Technology globally including product/technology development, extending clinical effectiveness, expansion of the Invisalign Technology brand and driving international growth. In a parallel press release today, the company has introduced an expanded Invisalign product portfolio offering new options and greater flexibility to a wider range of patients.
Earlier, the company had introduced a clear Aligner solution for teen Class II correction — the Invisalign Technology Teen with mandibular advancement — in certain markets of Canada, EMEA and APAC. These are indicative of the growing popularity of Align’s dental products in the international market. Over the long term, we expect G6, G7 and similar innovations to act as major catalysts for Align in the new as well as the existing markets.
Over the past six months, shares of Align have outperformed its industry. The stock has surged 33.1% compared with the 2.1% increase of the industry.
Zacks Rank & Key Picks
Align carries a Zacks Rank #2 (Buy). A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Edwards Lifesciences Corporation (EW - Free Report) .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. It has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>